An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours

Author: Awada A.   Thodtmann R.   Piccart M.J.   Wanders J.   Schrijvers A.H.G.J.   Von Broen I.-M.   Hanauske A.R.  

Publisher: Elsevier

ISSN: 0959-8049

Source: European Journal of Cancer, Vol.39, Iss.6, 2003-04, pp. : 742-747

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content